Research Progress and Clinical Prospects of Dendritic Cell Vaccines in Breast Cancer Immunotherapy

Abstract

Dendritic cell (DC) vaccines have shown significant research progress and clinical prospects in breast cancer immunotherapy. This article seeks to explain how dendritic cells (DC) show antigens in the immune environment of breast cancer and discuss the difficulties in creating and preparing DC vaccines to make them more effective. The advantages and disadvantages of DC vaccinations and other therapies were evaluated, combined application strategy of DC vaccines with other therapies such chemotherapy, immune checkpoint inhibitors, and radiotherapy was examined. By improving Presentation of an antigen and reducing T cell immunosuppression, the data demonstrated that DC vaccines can have a synergistic effect when used in conjunction with other treatments, greatly boosting the immune system that combats tumors. response. Compared with CAR-T cell therapy, DC vaccines are less likely to cause serious side effects such as cytokine storms. Compared with PD-L1 inhibitors, DC vaccines can actively activate the immune system, produce immune responses against specific tumor antigens, and have immune memory effects. To further enhance the design and administration of DC vaccines and increase their effectiveness in breast cancer immunotherapy, future research should concentrate on the creation of novel vaccine adjuvants, The discovery of new antigens related to tumors and the development of vaccine delivery methods.